(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

A new building of condominiums — including three affordable units — has been proposed for Brighton Center. Biotech's Future - ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

The U.S. Supreme Court preserved the U.S. Preventative Services Task Force coverage mandate that requires payers to cover certain preventive services at no cost to patients in a 6-3 ruling. That’s ...

An injection that can prevent HIV infection for six months has been approved by the US Food and Drug Administration (FDA).

Yes, the justices upheld a key part of the Affordable Care Act, but they also said our conspiracy theorist Health Secretary ...